Seeking Alpha04/11/2026 01:47:04

Compass Pathways outlines potential 30- to 60-day FDA review target as it plans to complete COMP360 NDA in next 2 weeks

Compass Pathways outlines potential 30- to 60-day FDA review target as it plans to complete COMP360 NDA in next 2 weeks

1 hour ago
View Original Source
Seeking Alpha

Seeking Alpha

Seeking Alpha is the leading platform for investors to research and discuss US-traded stocks and ETFs. Our platform helps investors to find successful investing ideas and to successfully manage their portfolios. It provides investment ideas, analysis, news, ratings, investing tools and community discussion.

More from Seeking Alpha

Hyperscalers Are Bleeding Cash And Losing Altitude

6 min ago

Crescent Energy outlines year-end 2027 leverage target of 1.5x following Devon Eagle Ford acquisition

11 min ago

Viper expects Q4 2026 oil production of 70,000 to 71,000 bbl/d as it raises FY 2026 midpoint to 67,500 bbl/d

11 min ago

Broadridge reaffirms fiscal 2027 8%-12% adjusted EPS growth while scaling tokenization and AI

11 min ago